ArticleBMC neurology2025
The potential role of serum and urine galectin-3 values in the diagnosis and staging of Parkinson's disease.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson’s disease (PD) is a progressive neurodegenerative disorder characterised by both motor and nonmotor symptoms. Galectin-3, a protein involved in the regulation of inflammatory responses, has emerged as a potential contributor to neurodegenerative processes. This study aimed to measure serum and urinary galectin-3 levels in patients with PD and to evaluate the associations of this biomarker with disease stages and clinical symptoms.
methodsThe present cross-sectional study included 30 PD patients and 29 healthy controls. Galectin-3 levels in serum and urine samples were measured via Enzyme-Linked Immunosorbent Assay (ELISA). The clinical data recorded included demographic information, Hoehn and Yahr (H&Y) stage, Unified Parkinson’s Disease Rating Scale (UPDRS) motor score, nonmotor symptom score (NMS), and total dopaminergic treatment dose parameters. Multivariate analyses were adjusted for age and sex due to demographic differences between groups.
resultsSerum galectin-3 optical density (OD) levels (0.2 [0.1–1.4]) and urinary galectin-3 OD levels (0.2 [0.1–0.6]) were significantly higher in PD patients than in controls (p < 0.050). Serum and urinary galectin-3 concentration (C) values were also elevated in the PD group. A moderate negative correlation was observed between serum galectin-3 levels and both the H&Y stage (r = − 0.418, p = 0.021) and the UPDRS motor score (r = − 0.541, p = 0.002). After adjusting for age and sex, serum galectin-3 C remained independently associated with motor severity. ROC analysis revealed that serum galectin-3 levels demonstrated promising diagnostic performance, with high specificity and sensitivity in distinguishing patients with PD from healthy controls (AUC = 0.716, p = 0.001). The serum/urine galectin-3 concentration ratio also showed significant discriminative value (AUC = 0.722, p = 0.035).
conclusionOur findings suggest that elevated levels of galectin-3 in serum and urine are associated with Parkinson’s disease and may reflect underlying neuroinflammatory mechanisms contributing to its pathophysiology. The diagnostic performance of galectin-3 markers remained robust even after adjusting for age and sex. However, the strict exclusion criteria and the age imbalance between groups may limit the generalizability of these results to broader clinical populations. Therefore, these findings should be considered exploratory and require confirmation through larger, longitudinal studies to determine their diagnostic and prognostic utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.